Fig. 7

NCAPG2 activates c-MYC expression via STAT3-mediated mechanism. a Immunofluorescence showed the colocalization of NCAPG2 and STAT3 in the nucleus of PCa cells (LNCaP cells was pre-treated with IL-6 at a concentration of 20 ng/mL for 24 h). b Co-IP assays showed that NCAPG2 directly bound to STAT3. c WB assay revealed that upregulation of NCAPG2 enhanced the c-MYC expression, while treatment with C188-9 (STAT3 inhibitor) could effectively reverse this effect. d ChIP assays indicated that STAT3 and NCAPG2 occupied on the region of MYC promoter. e Re-ChIP analysis demonstrated NCAPG2 and STAT3 formed a complex and occupied on MYC promoter region. f ChIP assay showed that silencing NCAPG2 suppressed STAT3 binding to MYC promoter region. PCa prostate cancer, co-IP co-immunoprecipitation, WB western blot, ChIP chromatin immunoprecipitation